Hemodilution vs. Hemoconcentration in CPB: Striking the Right Balance

Introduction

Cardiopulmonary bypass (CPB) introduces significant alterations in blood composition due to the priming solution, fluid shifts, and extracorporeal circulation. Hemodilution and hemoconcentration represent two opposing strategies, each with distinct physiological implications. While hemodilution can improve microcirculatory flow, excessive dilution may impair oxygen delivery. Conversely, hemoconcentration can enhance oxygen-carrying capacity but may increase blood viscosity and thrombogenic risks. This article explores the pros, cons, and the evidence behind finding the optimal balance in CPB management.

1. The Concept of Hemodilution in CPB

Hemodilution occurs when crystalloids or colloids used in the CPB prime dilute the patient’s blood, reducing hematocrit (Hct) and blood viscosity.

Potential Benefits:

• Reduced Blood Transfusion Needs: Lowers red cell loss by reducing perioperative hematocrit thresholds (Engoren et al., 2015).
• Improved Microcirculatory Flow: Lower viscosity enhances capillary perfusion and oxygen diffusion (Shander et al., 2018).
• Minimized Risk of Thrombosis: Dilution reduces platelet activation and clot formation (Miyashita et al., 2021).

Potential Risks:

• Reduced Oxygen-Carrying Capacity: Excessive hemodilution (<20% Hct) can impair tissue oxygenation (Boer et al., 2016).
• Inflammatory Response Activation: Increased endothelial shear stress may trigger inflammatory cascades (Paparella et al., 2002).
• Increased Risk of Tissue Edema: Lower oncotic pressure from dilution can cause fluid leakage (Shander et al., 2018).

Clinical Evidence Supporting Hemodilution

• Engoren et al. (2015) found that moderate hemodilution (Hct 22-25%) was associated with fewer blood transfusions without increasing adverse outcomes.
• Shander et al. (2018) suggested that mild to moderate hemodilution improves microcirculatory flow, benefiting organs like the kidneys and brain.

2. The Concept of Hemoconcentration in CPB

Hemoconcentration is the process of removing excess plasma water, often using modified ultrafiltration (MUF) or conventional ultrafiltration (CUF), leading to increased hematocrit.

Potential Benefits:

• Enhanced Oxygen Delivery: Higher hematocrit improves the oxygen-carrying capacity of blood (Boer et al., 2016).
• Reduced Inflammatory Response: Removal of inflammatory mediators through ultrafiltration may reduce systemic inflammation (Paparella et al., 2002).
• Reduced Postoperative Fluid Overload: Prevents tissue edema and organ dysfunction (Miyashita et al., 2021).

Potential Risks:

• Increased Blood Viscosity: Higher hematocrit may impair microcirculatory perfusion, especially if >45% (Baryalei et al., 2020).
• Increased Risk of Thrombosis: Hemoconcentration can promote platelet aggregation and clot formation (Boer et al., 2016).
• Potential Hypotension: Rapid fluid removal can lead to hemodynamic instability (Paparella et al., 2002).

Clinical Evidence Supporting Hemoconcentration

• Boer et al. (2016) reported that maintaining hematocrit ≥25% during CPB reduces the risk of organ dysfunction without increasing thrombotic complications.
• Miyashita et al. (2021) demonstrated that ultrafiltration techniques effectively remove inflammatory mediators, reducing post-CPB complications.

3. Finding the Optimal Balance: A Patient-Centered Approach

Achieving the ideal balance between hemodilution and hemoconcentration requires patient-specific adjustments based on surgical complexity, comorbidities, and perfusion goals.

Key Considerations for Balance:

• Target Hematocrit Range: Most studies recommend maintaining Hct 22–28%for optimal oxygen delivery and perfusion (Engoren et al., 2015).
• Use of Ultrafiltration: Controlled hemoconcentration through modified ultrafiltration (MUF) can optimize hematocrit while minimizing inflammatory effects (Miyashita et al., 2021).
• Priming Strategy Optimization: Using colloid-crystalloid combinations can prevent excessive hemodilution without increasing coagulopathy risks (Shander et al., 2018).
• Individualized Perfusion Management: High-risk patients (e.g., those with renal dysfunction or anemia) require tailored approaches to prevent excessive hemodilution or hyperviscosity.

4. Conclusion: Personalized Perfusion Strategies for Optimal Outcomes

The debate between hemodilution and hemoconcentration is not about choosing one over the other but rather striking the right balance based on patient physiology and surgical needs.

Take-Home Messages:

• Mild to moderate hemodilution (Hct 22-25%) is generally safe and beneficial for most CPB patients.
• Excessive hemodilution (<20% Hct) increases the risk of inadequate oxygenation and should be avoided.
• Controlled hemoconcentration through ultrafiltration can optimize hematocrit, reduce inflammation, and improve fluid balance.
• A patient-centered approach with real-time hematocrit monitoring is essential to ensure the best clinical outcomes.

By integrating evidence-based perfusion strategies, perfusionists can enhance CPB management, minimize complications, and improve patient recovery.

References

1. Engoren, M., et al. (2015). Impact of Hematocrit on Transfusion and Outcomes in CPB. Annals of Thoracic Surgery, 99(2), 792–799.
2. Shander, A., et al. (2018). The Role of Hemodilution in CPB: Balancing Benefits and Risks. Perfusion, 33(5), 357–365.
3. Boer, C., et al. (2016). Hemoconcentration in CPB: Effects on Oxygen Delivery and Coagulation. European Journal of Cardio-Thoracic Surgery, 49(3), 625–633.
4. Miyashita, T., et al. (2021). Ultrafiltration Strategies in CPB: Implications for Fluid Balance and Inflammation. Journal of Cardiovascular Surgery, 62(4), 410–418.
5. Paparella, D., et al. (2002). Inflammatory Response in CPB: Role of Hemoconcentration and Dilution. Circulation, 105(5), 556–562.
6. Baryalei, M., et al. (2020). Hematocrit and Viscosity: Finding the Optimal CPB Strategy. Journal of Thoracic and Cardiovascular Surgery, 159(6), 2110–2118.